Sanofi
Close on Oct 19, 2026
About Sanofi
Pharmaceutical Preparations, SIC 2834
The provided text consists of XBRL taxonomy tags and regulatory filing identifiers rather than descriptive business disclosures. Based on these data tags, the company operates across biopharmaceutical and consumer healthcare segments, with references to marketed biopharma products, technological platforms, and collaborative research initiatives. The excerpt contains no descriptive narrative detailing customer groups or services.
The excerpt provides no narrative facts concerning physical operational scale, retail stores, facility counts, or geographic distribution beyond individual taxonomy member strings. The text does not disclose the company's headquarters location.
Summary of the business section of Sanofi's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Sanofi
- Founded
- 2004
- Headquarters
- Paris, I0
- Address
- 46 Avenue De La Grande Armee 75017
- Phone
- 33153774400
- Website
- www.sanofi.com
- Employees
- 9,274, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- I0
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers Audit, Neuilly-sur-Seine and Levallois-Perret, France
Stock & identifiers
- Ticker
- SNY
- Other tickers
- SNYNF
- Exchange
- Nasdaq
- IPO date
- Jul 1, 2002
- Shares outstanding
- 1.22B, Dec 31, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1121404
- CUSIP
- 80105N105
- ISIN
- US80105N1054
- LEI
- 549300E9PC51EN656011
- EIN
- 13-3529324
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
No recent ownership filings by officers or directors
Sanofi's leadership is listed in its proxy statement (Form DEF 14A).
Employees
Headcount reported in annual reports
“2025 , we had 9,274 employees engaged in research and development activities.”
Corporate history
Events identified from SEC filings